menu
    • menu
    [{"orgOrder":0,"company":"Encube Ethicals","sponsor":"Novum Pharmaceutical Research Services | ACM Global Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Encube Ethicals \/ Novum Pharmaceutical Research Services | ACM Global Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ Novum Pharmaceutical Research Services | ACM Global Laboratories"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Novum Pharmaceutical Research Services | ACM Global Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NEW ZEALAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Douglas CDMO \/ Novum Pharmaceutical Research Services | ACM Global Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Douglas CDMO \/ Novum Pharmaceutical Research Services | ACM Global Laboratories"}]

    Find Clinical Drug Pipeline Developments & Deals for NCGC00025000-10

    Menu

    NCGC00025000-10

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Douglas CDMO

                            New Zealand
                            CPhI WW Frankfurt
                            Booth #9.1D6
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEnd-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Novum Pharmaceutical Research Services | ACM Global Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Therapeutic Equivalence Study of Ketoconazole Cream 2%

                            Details : Ketoconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tinea Pedis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 18, 2019

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Novum Pharmaceutical Research Services | ACM Global Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Douglas CDMO

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zydus Lifesciences

                            India arrow
                            ACI Convention
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Lifesciences Gets USFDA Nod to Market Generic Antifungal Shampoo

                            Details : Ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes. It is indicated for fungal skin conditions like dandruff.

                            Product Name : Ketoconazole-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

                            Details : Nizoral-Generic (ketoconazole) is an antifungal shampoo, which is indicated for the treatment of dandruff & scalp dermatoses.

                            Product Name : Nizoral-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2024

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicol...

                            Details : Ketoconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tinea Versicolor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2024

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Encube Ethicals

                            India arrow
                            ACI Convention
                            Not Confirmed

                            Encube Ethicals

                            India arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Novum Pharmaceutical Research Services | ACM Global Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedi...

                            Details : Ketoconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tinea Pedis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2019

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Novum Pharmaceutical Research Services | ACM Global Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eisai Inc

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Eisai Inc

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 ...

                            Details : Ketoconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 23, 2014

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            ACI Convention
                            Not Confirmed

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mu...

                            Details : Ketoconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 10, 2013

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            LG Life Sciences

                            South Korea arrow
                            ACI Convention
                            Not Confirmed

                            LG Life Sciences

                            South Korea arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic Drug Interaction Study in Healthy Male Subjects

                            Details : Ketoconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 01, 2011

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Johnson & Johnson

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known a...

                            Details : Ketoconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tinea Pedis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 26, 2010

                            Lead Product(s) : Ketoconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth